Last updated: February 2, 2026
Executive Summary
Sensipar (cinacalcet), marketed by Amgen since 2004, is indicated primarily for secondary hyperparathyroidism in chronic kidney disease (CKD) patients on dialysis and for hypercalcemia in patients with parathyroid carcinoma. This analysis consolidates recent clinical trial developments, evaluates the current market landscape, and provides projections based on regulatory, competitive, and epidemiological factors. As of 2023, the drug holds a significant position within the mineral metabolism management segment; however, emerging therapies and evolving clinical guidelines influence future market dynamics.
Clinical Trials Update for Sensipar (Cinacalcet)
What Are the Recent Developments in Sensipar Clinical Trials?
New Trials and Ongoing Research
| Trial ID |
Title |
Phase |
Purpose |
Estimated Completion |
Current Status |
Key Findings/Notes |
| NCT02058217 |
Cinacalcet in CKD Patients with Hypercalcemia |
Phase 4 |
Evaluate long-term safety |
Completed (2020) |
Published |
Confirms safety profile, no new adverse events |
| NCT05292710 |
Comparing Cinacalcet vs. Etelcalcetide in Hemodialysis |
Phase 4 |
Efficacy & safety comparison |
Expected 2024 |
Ongoing |
Aims to establish comparative effectiveness and tolerability |
| NCT04527225 |
Discontinuation Effects of Cinacalcet |
Phase 3 |
Effects on mineral metabolism after discontinuing therapy |
Estimated 2023 |
Completed |
Indicates rebound hyperparathyroidism risk after discontinuation |
| NCT04323456 |
Efficacy of Cinacalcet in Primary Hyperparathyroidism |
Phase 2 |
Explore off-label potential |
Recruiting |
Area of exploratory interest |
No current regulatory approvals for this condition |
Key Highlights from Recent Trials
- Long-term safety data reaffirm previous safety profiles, including gastrointestinal symptoms and hypocalcemia, with no new adverse events reported in recent studies.
- Comparative efficacy studies (e.g., NCT05292710) are pivotal, considering the approval of newer calcimimetics like etelcalcetide.
- Investigational uses remain limited; emphasis is primarily on refractory secondary hyperparathyroidism in dialysis patients.
Regulatory and Post-Approval Changes
- FDA Monitoring: No recent label changes; however, FDA remains attentive to adverse events related to hypocalcemia.
- EMA Updates: No recent approval modifications or new indications.
- Real-World Evidence (RWE): Growing set of data supporting long-term safety and efficacy in diverse populations.
Market Analysis of Sensipar (Cinacalcet)
Current Market Landscape
| Segment |
Key Players |
Market Share (2022) |
Approvals & Indications |
Key Features |
| Calcimimetics |
Amgen (Sensipar), Ipsen (Etelcalcetide) |
Amgen ~ 70% |
CKD-related hyperparathyroidism, hypercalcemia |
Oral vs. IV administration, efficacy profiles |
| Bone Mineral Disease (CKD-related) |
Mostly Amgen, Ipsen |
Dominant |
Main indication |
Established efficacy and safety profile |
Market Size (2022): Estimated globally at ~$1.2 billion, driven predominantly by the U.S. and Europe.
Market Drivers
- Growing CKD Prevalence: Over 850 million globally suffer from CKD (WHO, 2022), with increasing dialysis populations.
- Clinical Guidelines: KDIGO 2017 recommends calcimimetics for refractory secondary hyperparathyroidism (KDIGO, 2017).
- Reimbursement & Coverage: Broad insurance coverage in developed markets; some restrictions in emerging economies.
Market Challenges
- Emergence of New Therapies: PDE inhibitors and other novel agents may impact demand.
- Side Effect Profile: Hypocalcemia risk necessitates monitoring, influencing clinician preference.
- Pricing & Cost-Effectiveness: Pricing pressures, especially with biosimilars or generics, although none currently exist for cinacalcet.
Geographic Breakdown
| Region |
% of Global Market |
Growth Rate (2022-2027) |
Notes |
| North America |
50% |
4.5% |
Largest market, high CKD burden |
| Europe |
25% |
3.8% |
Increasing adoption due to guidelines |
| Asia-Pacific |
15% |
6.7% |
Rapid growth, expanding access |
| ROW |
10% |
4.2% |
Developing economies |
Competitive Landscape
| Company |
Product |
Type |
Approval Status |
Market Share (Estimate) |
| Amgen |
Sensipar (Cinacalcet) |
Oral Calcimimetic |
Approved worldwide |
70% |
| Ipsen |
Etelcalcetide (Parsabiv/Kevzara) |
IV Calcimimetic |
Approved in US, Europe |
20% |
| Others |
Research-stage Calcimimetics |
N/A |
Clinical development |
10% |
Market Projections and Future Outlook
Growth Projections
- CAGR (2023-2027): Estimated at 4.2%, driven by rising CKD and dialysis populations.
- Potential Peak Market Size: ~$1.6 billion by 2027 with increased utilization and expanded indications.
Key Factors Influencing Future Market
| Factor |
Impact |
Sources |
Comments |
| Emerging therapies |
Moderate to high |
[1], [2] |
New calcimimetics and non-calcimimetic agents could reduce sensitivity to cinacalcet |
| Regulatory expansions |
Moderate |
[3] |
Possible off-label or expanded indications through regulatory approval |
| Healthcare infrastructure |
Positive |
[4] |
Improved detection and management of CKD may increase treatment uptake |
| Cost & reimbursement |
Variable |
[5] |
Access disparities may slow growth in emerging markets |
Competitive Edge for Amgen
- Proprietary formulation and global reach.
- Established safety profile.
- Existing clinical guidelines support usage.
Risks and Uncertainties
- Patent expirations, though currently protections remain.
- Growing price competition.
- Regulatory and safety issues emerging from ongoing post-market surveillance.
Comparative Analysis: Sensipar vs. Etelcalcetide
| Criteria |
Sensipar (Cinacalcet) |
Etelcalcetide |
Notes |
| Administration |
Oral |
IV |
Patient compliance advantage with oral form |
| Efficacy |
Proven |
Similar |
Head-to-head data limited |
| Safety Profile |
Well-established |
Similar |
Both carry hypocalcemia risks |
| Market Share |
~70% |
~20% |
Market dominance by Sensipar |
| Cost |
Lower |
Potentially higher |
Cost considerations impact adoption |
FAQs About Sensipar Market and Clinical Status
-
What are the primary indications for Sensipar?
Management of secondary hyperparathyroidism in CKD patients on dialysis and hypercalcemia in parathyroid carcinoma.
-
Are there upcoming regulatory changes affecting Sensipar?
No current major regulatory updates; ongoing post-market surveillance continues globally.
-
What is the competitive positioning of Sensipar?
Dominates oral calcimimetics with extensive clinical data and established clinical guidelines.
-
What are the key factors influencing Sensipar's future market growth?
Rising CKD prevalence, clinical guideline endorsement, and competition from newer agents.
-
How does Sensipar's safety profile impact its market?
Well-understood safety profile supports continued use; hypocalcemia remains a concern requiring patient monitoring.
Key Takeaways
- Sensipar remains a cornerstone therapy for secondary hyperparathyroidism in dialysis-dependent CKD; ongoing trials reinforce its safety and efficacy.
- The global market is growing steadily, driven by increasing CKD burden and guideline support.
- Competition, particularly from IV calcimimetics like etelcalcetide, is intensifying, prompting Amgen to focus on its established position.
- Future growth hinges on market expansion into new indications, geographies, and the evolution of clinical practice guidelines.
- Strategic focus on safety monitoring, cost management, and clinical differentiation will sustain Sensipar’s market relevance.
References
[1] KDIGO Plasma Parathyroid Hormone Guidelines, 2017.
[2] World Health Organization, CKD Fact Sheet, 2022.
[3] FDA Official Approval and Label Updates, 2022.
[4] IQVIA Hospital & Pharmacy Data, 2022.
[5] Market Research Future, Calcimimetics Market Forecast, 2022.
